Related references
Note: Only part of the references are listed.Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients
Yakup Bozkaya et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial
Yasuhide Yamada et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
Ken Kato et al.
GASTRIC CANCER (2019)
Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer
Tsutomu Namikawa et al.
GASTRIC CANCER (2019)
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Sakura Iizumi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara et al.
LANCET ONCOLOGY (2018)
Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients
Yukiya Narita et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
Valentina Fanotto et al.
GASTRIC CANCER (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
Charles S. Fuchs et al.
JOURNAL OF GASTRIC CANCER (2017)
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
A. Custodio et al.
BRITISH JOURNAL OF CANCER (2017)
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
Kohei Shitara et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Kohei Shitara et al.
GASTRIC CANCER (2016)
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
S. -E. Al-Batran et al.
ANNALS OF ONCOLOGY (2016)
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial
T. Grenader et al.
ANNALS OF ONCOLOGY (2016)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lauren classification and individualized chemotherapy in gastric cancer (Review)
Junli Ma et al.
ONCOLOGY LETTERS (2016)
Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
Fausto Petrelli et al.
ACTA ONCOLOGICA (2015)
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer
Y. Yamada et al.
ANNALS OF ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy
Yasuo Hamamoto
MOLECULAR AND CLINICAL ONCOLOGY (2015)
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
Y. Kurokawa et al.
BRITISH JOURNAL OF CANCER (2014)
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912
Atsuo Takashima et al.
GASTRIC CANCER (2014)
Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association
Hideaki Shimada et al.
GASTRIC CANCER (2014)
Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment
Shigenori Kadowaki et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
Wasaburo Koizumi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E. R. Ford et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Determination of Prognostic Factors in Japanese Patients With Advanced Gastric Cancer Using the Data From a Randomized Controlled Trial, Japan Clinical Oncology Group 9912
Daisuke Takahari et al.
ONCOLOGIST (2014)
High Lactate Dehydrogenase 5 Expression Correlates with High Tumoral and Stromal Vascular Endothelial Growth Factor Expression in Gastric Cancer
Hee Sung Kim et al.
PATHOBIOLOGY (2014)
Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
Shuichi Hironaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination
Shigenobu Emoto et al.
GASTRIC CANCER (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models
Dong Hoe Koo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
D. Kanagavel et al.
ANNALS OF ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer
Hye Jin Kim et al.
ACTA ONCOLOGICA (2009)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
Narikazu Boku et al.
LANCET ONCOLOGY (2009)
Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer:: Association with hypoxia-inducible factor (HIF-1α) pathway, angiogenic factors production and poor prognosis
Yanislav Kolev et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
V. Catalano et al.
BRITISH JOURNAL OF CANCER (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy
Jong Gwang Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma
J. Lee et al.
ANNALS OF ONCOLOGY (2007)
Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma
Joon Seok Lim et al.
KOREAN JOURNAL OF RADIOLOGY (2006)
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data
I Chou et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer
T Nakagoe et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2001)
Share Paper
